Allogeneic stem cell transplantation: the last century -- Full intensity and reduced intensity allogeneic transplantation in AML -- Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia (ALL) -- Hematopoietic progenitor cell transplantation for treatment of chronic lymphocytic leukemia -- The role of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients in the era of tyrosine kinase inhibitors -- Allogeneic transplantation for Hodgkin's lymphoma -- Myeloablative allogeneic stem cell transplantation for non-Hodgkin's lymphoma -- Non-Hodgkin's lymphoma: allogeneic reduced intensity conditioning -- The role of allogeneic transplantation for multiple myeloma in older adults -- Single versus tandem autologous hematopoietic stem cell transplant in multiple myeloma -- Treatment strategies for follicular center cell non-Hodgkin's lymphoma -- The role of transplantation in favorable-risk acute myeloid leukemia -- Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adults -- Allogeneic transplantation for myelodysplastic syndromes -- Allogeneic hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia -- Allogeneic transplantation for the treatment of multiple myeloma -- Blood vs. marrow allogeneic stem cell transplantation -- Hematopoietic cell transplantation from partially HLA-mismatched (HLA-haploidentical related donors) -- Unrelated donor transplants -- Update on umbilical cord blood transplantation -- Selection of cord blood unit(s) for transplantation -- Mobilization of hematopoietic cells prior to autologous or allogeneic transplantation -- Natural killer-cell based treatment in hematopoietic stem cell transplantation -- Cryopreservation of allogeneic stem cell products -- Concepts and controversies in the use of novel preparative regimens for allogeneic stem cell transplantation -- Allogeneic hematopoietic stem cell transplantation and natural killer cell alloreactivity -- Therapeutic potential of mesenchymal stem cells in hematopoietic stem cell transplantation -- Hematopoietic stem cell transplantation for thalassemia -- Viral infections in hematopoietic stem cell transplant recipients -- Fungal infections -- Immune reconstitution and implications for immunotherapy following hematopoietic stem cell transplantation -- Acute graft versus host disease: prophylaxis -- Chronic graft versus host disease -- Post-transplant lymphoproliferative disorder -- Psychological care of adult allogeneic transplant patients -- Second allogeneic transplantation: outcomes and indications -- Minimal residual disease -- Functional assessment tools and co-morbidity scoring in hematopoietic progenitor cell transplantation -- Unique thrombotic and hemostatic complications associated with allogeneic hematopoietic stem cell transplantation -- How much isolation is enough for allografts? -- Monoclonal antibodies in allogeneic hematopoietic stem cell transplantation for hematologic malignancies -- Treatment of actue graft versus host disease -- The importance of non-human primate models for pre-clinical studies in hematopoiesis -- In vivo models of allogeneic hematopoietic stem cell transplantation -- Dendritic cells -- Augmentation of hematopoietic stem cell transplantation with anti-cancer vaccines